Cognition Therapeutics (CGTX) Competitors $0.45 0.00 (0.00%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CGTX vs. IMAB, ELYM, GBIO, HOWL, OVID, PYRGF, FBLG, AVTE, EPIX, and UNCYShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include I-Mab (IMAB), Eliem Therapeutics (ELYM), Generation Bio (GBIO), Werewolf Therapeutics (HOWL), Ovid Therapeutics (OVID), PyroGenesis Canada (PYRGF), FibroBiologics (FBLG), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. I-Mab Eliem Therapeutics Generation Bio Werewolf Therapeutics Ovid Therapeutics PyroGenesis Canada FibroBiologics Aerovate Therapeutics ESSA Pharma Unicycive Therapeutics I-Mab (NASDAQ:IMAB) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Which has more volatility and risk, IMAB or CGTX? I-Mab has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Do institutionals & insiders believe in IMAB or CGTX? 38.4% of I-Mab shares are held by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is IMAB or CGTX more profitable? I-Mab's return on equity of 0.00% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A N/A N/A Cognition Therapeutics N/A -150.93%-100.82% Do analysts recommend IMAB or CGTX? I-Mab presently has a consensus price target of $8.00, suggesting a potential upside of 746.29%. Cognition Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 1,658.63%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cognition Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings and valuation, IMAB or CGTX? Cognition Therapeutics has lower revenue, but higher earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.27M23.54-$206.44MN/AN/ACognition TherapeuticsN/AN/A-$25.79M-$0.97-0.47 Does the MarketBeat Community believe in IMAB or CGTX? I-Mab received 42 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 65.38% of users gave Cognition Therapeutics an outperform vote while only 64.13% of users gave I-Mab an outperform vote. CompanyUnderperformOutperformI-MabOutperform Votes5964.13% Underperform Votes3335.87% Cognition TherapeuticsOutperform Votes1765.38% Underperform Votes934.62% Does the media favor IMAB or CGTX? In the previous week, Cognition Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Cognition Therapeutics and 1 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Cognition Therapeutics' score of 0.10 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryI-Mab beats Cognition Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.90M$2.98B$5.17B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-0.4746.24127.7717.55Price / SalesN/A409.351,261.39139.05Price / CashN/A182.1341.0437.95Price / Book0.603.924.894.92Net Income-$25.79M-$42.03M$119.40M$225.78M7 Day Performance4.94%-4.04%14.54%-1.47%1 Month Performance-1.37%6.85%17.43%5.36%1 Year Performance-77.70%20.53%35.31%22.71% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.6982 of 5 stars$0.45flat$8.00+1,658.6%-77.7%$18.90MN/A-0.4720IMABI-Mab2.4476 of 5 stars$0.95-4.8%$8.00+740.5%-32.0%$77.57M$3.27M0.0034ELYMEliem TherapeuticsN/A$2.60-7.8%N/A-11.4%$77.36MN/A-4.9120Positive NewsGap DownGBIOGeneration Bio2.8785 of 5 stars$1.14-1.7%$7.50+557.9%-45.5%$76.14M$18.58M-0.53150Gap DownHOWLWerewolf Therapeutics3.8119 of 5 stars$1.70+2.7%$12.00+608.0%-45.2%$75.53M$3.39M-1.0840Short Interest ↓News CoveragePositive NewsOVIDOvid Therapeutics4.4901 of 5 stars$1.06+2.4%$4.04+282.9%-69.2%$74.92M$390,000.000.0060News CoveragePositive NewsGap DownPYRGFPyroGenesis CanadaN/A$0.41-1.3%N/A+21.3%$74.54M$9.14M-6.8490FBLGFibroBiologics1.6988 of 5 stars$2.12-4.5%$13.00+513.2%N/A$73.48MN/A0.0010Short Interest ↑AVTEAerovate Therapeutics1.3772 of 5 stars$2.53flat$2.25-11.1%-85.8%$73.05MN/A-0.8551Short Interest ↓News CoveragePositive NewsEPIXESSA Pharma3.5062 of 5 stars$1.64flat$9.50+479.3%-73.7%$72.77MN/A-2.6550Earnings ReportNews CoveragePositive NewsUNCYUnicycive Therapeutics3.7874 of 5 stars$0.70-2.0%$5.13+632.1%+22.2%$72.66M$680,000.00-0.749Positive News Related Companies and Tools Related Companies I-Mab Competitors Eliem Therapeutics Competitors Generation Bio Competitors Werewolf Therapeutics Competitors Ovid Therapeutics Competitors PyroGenesis Canada Competitors FibroBiologics Competitors Aerovate Therapeutics Competitors ESSA Pharma Competitors Unicycive Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
